Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics

17th November 2017 (Last Updated November 17th, 2017 00:00)

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125 a share.

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125 a share.

The US-based ribonucleaic acid interference (RNAi) therapeutics company plans to use the funds for general corporate purposes, as well as research and development (R&D) activities.

Myovant Sciences plans to issue securities to raise $300m.

The securities include common shares, preference shares, debt securities, and warrants.

The company plans to use the proceeds towards clinical development programmes for relugolix and for general corporate purposes.

Denali Therapeutics plans to raise $100m through an initial public offering (IPO) of shares of its common stock.

"Odonate Therapeutics plans to raise $172.5m through an initial public offering (IPO) of shares of its common stock."

The US-based neurodegenerative diseases company intends to use the funds towards Phase I and II trials and general corporate purposes.

Arcus Biosciences Inc has secured $107m in a series C funding round led by GV.

Formerly known as Google Ventures, this US-based biotechnology company plans to use the funds to progress the clinical programmes for AB928.

Odonate Therapeutics plans to raise $172.5m through an initial public offering (IPO) of shares of its common stock.

The US-based discovery-stage company plans to use the funds towards clinical studies of tesetaxel and general corporate purposes.

Sage Therapeutics plans to issue a public offering of three million shares of its common stock priced at $85 a share to raise $300m.

The US-based clinical-stage biopharmaceutical company plans to use the funds for new drug application (NDA) submission of brexanolone and general corporate purposes.